Psyence Biomedical Ltd. PBM

PBM announced up to US$5 million investment in PsyLabs and a reciprocal share exchange valued at about US$9 million per side to advance a planned U.S. ibogaine program for opioid use disorder. PBM will subscribe US$2.4 million in PsyLabs shares (936 shares) as part of PsyLabs' financing, with up to US$2.6 million more in milestone-based tranches that expire if not drawn by December 31, 2026. The reciprocal exchange will see PBM issue 1,497,500 PBM common shares to PsyLabs and PsyLabs issue 3,473 PsyLabs ordinary shares to PBM (each valued at roughly US$8.99 million). Immediately after closing, PsyLabs will hold about 49.89% of PBM, and PBM will hold about 41.13% of PsyLabs. A newly formed Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), will coordinate U.S. regulatory, clinical and development activities. The coupling aligns PBM's ibogaine program with PsyLabs' pharmaceutical-grade manufacturing, subject to regulatory approvals. Major strategic alignment with PsyLabs, funding and cross-ownership create potential for a significant shift in PBM's trajectory through U.S. ibogaine development, though dependent on regulatory approvals and milestones.

Psyence BioMed establishes Texas Ibogaine Research Corporation to advance U.S. ibogaine development. Dedicated Texas research entity advances core ibogaine initiatives and U.S. market positioning.

Psyence BioMed welcomes U.S. Administration action to accelerate ibogaine development. U.S. acceleration of ibogaine development directly advances Psyence BioMed's core psychedelic drug pipeline.

Psyence Biomedical Ltd. (PBM) announces U.S. strategic engagement initiative focused on GMP ibogaine research and manufacturing. U.S. GMP ibogaine initiative marks major strategic expansion enhancing research capabilities and market positioning.

FDA fast-tracks psychedelic drug research following Trump directive, boosting shares of psychedelic drug makers including Psyence Biomedical Ltd. (PBM). FDA fast-track accelerates psychedelic drug development, significantly aiding PBM's pipeline and market performance.

Psyence Biomedical Ltd. (PBM) initiates patient dosing in Phase IIb clinical trial evaluating NPX-5 for Adjustment Disorder treatment. Initiating Phase IIb dosing marks a major clinical milestone advancing NPX-5 toward potential approval and boosting PBM's pipeline value.

Psyence Biomedical Ltd. (PBM) secures position as the world's only licensed supplier of pharmaceutical-grade ibogaine directly at the source. Exclusive global licensing for pharmaceutical-grade ibogaine at source fundamentally redefines PBM's competitive dominance and long-term market prospects.

Psychedelic shares, including Psyence Biomedical Ltd. (PBM), rose sharply after President Trump's executive order directing the FDA to accelerate approvals for innovative treatments targeting serious mental illnesses. Trump's executive order accelerates FDA approvals for mental health treatments, directly boosting PBM's psychedelic therapy pipeline and market sentiment.

President Trump to sign executive order promoting psychedelic treatments for PTSD, fueling 'Trump Trade' momentum for Psyence Biomedical Ltd. (PBM), a leader in psilocybin therapies. Presidential executive order on psychedelics for PTSD poised to redefine regulatory barriers and skyrocket demand for PBM's core psilocybin PTSD treatments.

Psyence Biomedical Ltd. welcomes U.S. executive action to advance research into ibogaine. U.S. executive action advancing ibogaine research supports Psyence BioMed's psychedelics pipeline, potentially accelerating development and boosting market sentiment.

Psyence Biomedical Ltd. expands its Australian clinical site network to five sites, accelerating NPX-5-supported clinical activities. Expanding clinical sites advances key NPX-5 trials, moderately boosting product development and market sentiment.

Psyence Biomedical Ltd. (PBM) advances its vertically integrated pharmaceutical platform following PsyLabs' export milestone, strengthening its corporate strategy. Vertical integration progress and export milestone enable major strategic expansion and competitive enhancement for PBM.

Helus Pharma announced results from the Phase 2 signal detection study for HLP004, a psychedelic therapy candidate linked to Psyence Biomedical Ltd. (PBM). Phase 2 results for HLP004 mark a major clinical milestone that could accelerate PBM's drug development pipeline and drive substantial investor interest.

Psyence Biomedical Ltd. announces export of GMP-manufactured natural psilocybin (NPX-5) to Australia for ongoing Phase IIb clinical trial. Exporting GMP psilocybin for Phase IIb trial advances key clinical pipeline and strengthens competitive positioning in psychedelics biotech.

Psyence Biomedical Ltd. announces PsyLabs exercised its put option and a strategic equity investment. Strategic equity investment and put option exercise signal major financial restructuring with potential to alter Psyence Biomedical Ltd.'s trajectory.

Psyence Biomedical Ltd. has approved a put option agreement with PsyLabs to secure a strategic supply of products, which is expected to enhance its commercialization pathway. This agreement aims to strengthen the company's operational capabilities and market position. The strategic supply agreement is likely to significantly impact Psyence's future operations and market performance.

Psyence Biomedical Ltd. has reached a settlement in a shareholder litigation case, resolving disputes related to the company's operations and governance. The settlement aims to enhance corporate governance and ensure better communication with shareholders moving forward. Details of the settlement terms have not been disclosed, but the company expresses optimism about the future and its commitment to shareholder interests. The settlement may improve corporate governance and shareholder relations, but its overall impact on the company's trajectory is expected to be limited.

Psyence Biomedical Ltd. announced the effective date for a 1-for-6.25 reverse stock split, which is set to take effect on a specified date. This move is part of the company's strategy to enhance its stock price and comply with listing requirements. Shareholders will receive one new share for every 6.25 shares they currently hold, and the reverse split is expected to improve the company's market perception and facilitate future financing efforts. The reverse stock split may moderately influence market perception and financial performance but is not expected to fundamentally alter the company's trajectory.

Psyence Biomedical Ltd. announced the effective date for a 1-for-6.25 reverse stock split, which is set to take effect on a specified date. This move is part of the company's strategy to enhance its stock price and comply with listing requirements. Shareholders will receive one new share for every 6.25 shares they currently hold, and the company aims to improve its market position through this adjustment. The reverse stock split may influence market perception and financial metrics, but its overall impact on the company's long-term trajectory is expected to be limited.

Psyence Biomedical Ltd. has approved its financial strategy for 2026 and authorized a share buyback program, aiming to capitalize on perceived value opportunities in the market. This strategic move is expected to enhance shareholder value and reflect confidence in the company's future prospects. The approval of a financial strategy and share buyback program indicates significant strategic moves that could positively influence investor sentiment and the company's market performance.

Psyence Biomedical Ltd. has successfully achieved a significant milestone in the production of natural Ibogaine HCl, enhancing its operational capabilities. Additionally, the company has strengthened its financial position, reporting no debt and holding $12 million in cash, which positions it favorably for future growth and development. The achievement in Ibogaine production and a strong cash position are likely to significantly impact the company's future operations and market perception.

Psyence Biomedical Ltd. has received approval for the use of its PsyLabs’ psilocybin product in a Phase IIb clinical trial. This trial aims to evaluate the efficacy and safety of the psilocybin product for treating various conditions, marking a significant step in the company's research and development efforts in the psychedelic medicine sector. Approval for a Phase IIb clinical trial is a significant regulatory milestone that could enhance product development and market positioning.

Psyence Biomedical Ltd. CEO highlights the company's clinical advancements in ibogaine therapy, emphasizing ethical sourcing practices and a robust cash position. The letter also outlines the company's commitment to leadership in longevity science, showcasing its strategic direction and potential for growth in this emerging field. Significant advancements in clinical progress and ethical sourcing could enhance the company's market position and investor sentiment.

Psyence Biomedical Ltd. has launched a pioneering research program focused on the longevity effects of psilocybin, a psychedelic compound. This initiative aims to explore the potential benefits of psilocybin in extending lifespan and improving healthspan. The program is part of Psyence's broader commitment to advancing psychedelic research and developing innovative therapies. The company plans to collaborate with leading researchers and institutions to conduct rigorous studies in this emerging field. The launch of a groundbreaking research program in psilocybin longevity could significantly enhance the company's strategic positioning and investor interest in the psychedelic sector.

Psyence Biomedical Ltd. has achieved a significant milestone by securing a reliable supply of pharmaceutical-grade ibogaine, aimed at meeting the growing demand in clinical and therapeutic markets worldwide. This breakthrough positions the company to enhance its product offerings and expand its market presence in the psychedelic medicine sector. Securing a reliable supply of pharmaceutical-grade ibogaine is a major strategic move that could significantly alter the company's trajectory and investor sentiment.

Psyence Biomedical Ltd. has established ibogaine operations in Africa through a strategic investment in PsyLabs. This move aims to enhance the company's capabilities in psychedelic medicine, particularly focusing on the therapeutic potential of ibogaine for addiction treatment. The investment is expected to bolster Psyence's position in the growing market for psychedelic therapies, aligning with global trends in mental health treatment. The establishment of ibogaine operations represents a significant strategic move that could enhance market positioning and investor sentiment.

Psyence Biomedical Ltd. has initiated dosing for multiple patients in its Phase IIb clinical study targeting adjustment disorder in palliative care. The company is also expanding its clinical sites to enhance the study's reach and effectiveness, aiming to address mental health challenges faced by patients in palliative settings. The expansion of clinical sites and patient dosing in a significant study could greatly influence the company's future performance and market perception.

Psyence Biomedical Ltd. has announced a follow-on investment of USD $3,500,000 to strengthen its strategic partnership with PsyLabs. This investment aims to enhance collaboration and support the development of innovative solutions in the psychedelic sector, reflecting Psyence's commitment to advancing its business objectives and expanding its market presence. The significant follow-on investment indicates a major strategic move that could enhance Psyence's competitive positioning and market dynamics.

Psyence Biomedical Ltd. has achieved a significant breakthrough in the production of high-purity ibogaine, a compound derived from the iboga plant. This advancement is expected to enhance the company's capabilities in developing therapeutic applications for mental health treatments. The new production method promises to improve the quality and consistency of ibogaine, positioning Psyence as a leader in this emerging market. The company aims to leverage this innovation to expand its product offerings and meet growing demand in the psychedelic therapy sector. The breakthrough in high-purity ibogaine production is likely to significantly enhance Psyence's competitive position and market opportunities in the therapeutic landscape.

Psyence Biomedical Ltd. (PBM) is set to present at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. This event will provide an opportunity for the company to showcase its developments and engage with investors. Participation in a significant investment conference may enhance visibility and investor interest, impacting market sentiment.